MEPs propose ways to make medicines more affordable

New medicine prices in the EU have risen over the past few decades, to the point of being unaffordable for many EU citizens and threatening the sustainability of national health care systems.

To strike a better balance between EU countries’ public health interests and those of the pharmaceutical industry, it calls for measures to improve the traceability of R&D costs, public funding and marketing expenditure.